TransformingPersonalized Medicine

Image for About NeoStem

About NeoStem

NeoStem is a biopharmaceutical company developing novel cell based personalized medicine therapies.

Learn More

 

TargetingCancer

Image for Metastatic melanoma

Metastatic melanoma

NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.

Learn More 

Enhancingthe body’s healing response

Image for Acute myocardial infarction – STEMI

Acute myocardial infarction – STEMI

NeoStem is developing a cell therapeutic applicable for multiple cardiovascular indications with an ongoing Phase 2 study for acute myocardial infarction.

Learn More

Rebalancingthe immune system

Image for Type 1 diabetes

Type 1 diabetes

NeoStem is developing an immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders.

Learn More

Innovatingdevelopment and manufacturing of cell-based therapies

Image for Client Services

Client Services

NeoStem’s subsidiary, PCT, provides development manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.

Learn More

News + Events

News + Events

 
NeoStem Prices $25,000,000 Public Offering of Common Stock May 27, 2015 - Learn More
 
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma May 26, 2015 - Learn More
 
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem May 21, 2015 - Learn More
 
 

NeoStem Blog

CEO Letter to NeoStem Shareholders

Dear NeoStem Shareholders, As you might imagine, the first two months of my tenure as the Chief Executive O.... Read More

Strengthening NeoStem’s Executive Management with Two Significant Hires

After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More